Evidence map›Paper›PMID 40425456›Full record

ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2025

[Comparison of the efficacy of continuous VA chemotherapy and I/HDAC consolidation in postremission therapy for acute myeloid leukemia fit for standard chemotherapy].

L Sun, P P Zhang, S M Ren, N Zhou, L Y Li, Z Z Wang, W G Cui, F Yang, J M Luo, L Yang

Abstract readComparative StudyEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

L SunDepartment of Hematology, the Second Hospital of Hebei Medical University, Key Laboratory of Hematology, Shijiazhuang 050000, China.
P P ZhangDepartment of Hematology, the Second Hospital of Hebei Medical University, Key Laboratory of Hematology, Shijiazhuang 050000, China.
S M RenBeijing Hospital, Institute of Geriatric Medicine, National Center for Clinical Laboratories, National Center of Gerontology, Chinese Academy of Medical Sciences, Beijing100730, China.
N ZhouDepartment of Hematology, the Second Hospital of Hebei Medical University, Key Laboratory of Hematology, Shijiazhuang 050000, China.
L Y LiDepartment of Hematology, the Second Hospital of Hebei Medical University, Key Laboratory of Hematology, Shijiazhuang 050000, China.
Z Z WangDepartment of Hematology, the Second Hospital of Hebei Medical University, Key Laboratory of Hematology, Shijiazhuang 050000, China.
W G CuiDepartment of Hematology, the Second Hospital of Hebei Medical University, Key Laboratory of Hematology, Shijiazhuang 050000, China.
F YangDepartment of Hematology, the Second Hospital of Hebei Medical University, Key Laboratory of Hematology, Shijiazhuang 050000, China.
J M LuoDepartment of Hematology, the Second Hospital of Hebei Medical University, Key Laboratory of Hematology, Shijiazhuang 050000, China.
L YangDepartment of Hematology, the Second Hospital of Hebei Medical University, Key Laboratory of Hematology, Shijiazhuang 050000, China.

Funding

The Natural Science Foundation of Beijing-Tianjin- Hebei Cooperation Project, China H2023206914Translational Research Grant of National Clinical Research Center of Hematologic disease 2021WWB07
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsLeukemia, Myeloid, AcuteAdultAgedAzacitidineBridged Bicyclo Compounds, HeterocyclicConsolidation ChemotherapyCytarabineDisease-Free SurvivalFemaleHumansMaleMiddle AgedRetrospective StudiesSulfonamidesTreatment OutcomeAzacitidineBridged Bicyclo Compounds, HeterocyclicCytarabineSulfonamidesvenetoclaxAgedCytarabineLeukemia, myeloid, acutePost-remission treatmentVenetoclax

Identifiers

PMID40425456
PMCPMC12158803

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.